Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1726377
PUBLISHER: Grand View Research | PRODUCT CODE: 1726377
U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Service, By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Small Molecule Innovator API CDMO Market Growth & Trends:
The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.
Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.
The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.
The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited's Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.
U.S. Small Molecule Innovator API CDMO Market Report Highlights:
- Based on stage, the clinical segment led the market with the largest revenue share of 54.68% in 2024. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
- Based on the customer type, the pharmaceutical segment held the market with the largest revenue share in 2024, attributing to rising funding for drug development is propelling segment growth
- Based on therapeutic area, the oncology segment accounted for the largest revenue share in 2024. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
- West Group dominated the U.S. market with the largest revenue share of 33.07% in 2024. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly
Product Code: GVR-4-68040-297-9
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Regional Scope
- 1.1.2. Estimates and Forecast Timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Purchased Database
- 1.3.3. GVR's Internal Database
- 1.3.4. Secondary Sources
- 1.3.5. Primary Research
- 1.4. Information or Data Analysis
- 1.4.1. Information Analysis
- 1.4.2. Market Formulation & Data Visualization
- 1.4.3. Data Validation & Publishing
- 1.5. Model Details
- 1.5.1. Commodity Flow Analysis (Model 1)
- 1.5.2. Top Down Market Estimation (Model 2)
- 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
- 1.5.4. Multivariate Analysis (Model 4)
- 1.6. List of Secondary Sources
- 1.7. List of Abbreviations
- 1.8. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Investments & Funding Perspective
- 3.5. Clinical Trials Volume Analysis, (2024)
- 3.5.1. Total Number of Clinical Trials, by Phase (2024)
- 3.5.2. Total Number of Clinical Trials, by Study Design (2024)
- 3.5.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
- 3.6. Technology Landscape
- 3.6.1. Integration Of AI In Small Molecule Innovator API CDMO Market
- 3.7. Pricing Model Analysis
- 3.8. Regulatory Framework
- 3.9. Industry Analysis Tools
- 3.9.1. Porter's Five Forces Analysis
- 3.9.2. PESTEL by SWOT Analysis
- 3.9.3. COVID-19 Impact Analysis
Chapter 4. U.S. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. U.S. Small Molecule Innovator API CDMO Market; Stage Type Movement Analysis
- 4.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
- 4.4. Preclinical
- 4.4.1. Preclinical market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Clinical
- 4.5.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.2. Phase I
- 4.5.2.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.3. Phase II
- 4.5.3.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.4. Phase III
- 4.5.4.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Commercial
- 4.6.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Small Molecule Innovator API CDMO Market: Service Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. U.S. Small Molecule Innovator API CDMO Market; Service Movement Analysis
- 5.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
- 5.4. Process Development
- 5.4.1. Process development market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Preclinical development
- 5.4.2.1. Preclinical development market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Clinical development
- 5.4.3.1. Clinical development market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Scale-up optimization
- 5.4.4.1. Scale-up optimization market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Contract Manufacturing
- 5.5.1. Contract manufacturing market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2. Clinical
- 5.5.2.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.3. Commercial
- 5.5.3.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Analytical Testing and Quality Control
- 5.6.1. Analytical testing and quality control market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Packaging and Supply Chain Solutions
- 5.7.1. Packaging and supply chain solutions market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Others
- 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. U.S. Small Molecule Innovator API CDMO Market; Customer Type Movement Analysis
- 6.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
- 6.4. Pharmaceutical
- 6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.2. Small
- 6.4.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.3. Medium
- 6.4.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.4. Large
- 6.4.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Biotechnology
- 6.5.1. Biotechnology market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Small
- 6.5.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. Medium
- 6.5.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Large
- 6.5.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. U.S. Small Molecule Innovator API CDMO Market; Therapeutic Area Movement Analysis
- 7.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
- 7.4. Cardiovascular Diseases
- 7.4.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Oncology
- 7.5.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Respiratory Disorders
- 7.6.1. Respiratory disorders market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Neurology
- 7.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. Metabolic Disorders
- 7.8.1. Metabolic disorders market estimates and forecasts 2018 to 2030 (USD Million)
- 7.9. Infectious Diseases
- 7.9.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 7.10. Others
- 7.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. Small Molecule Innovator API CDMO Market: Regional Business Analysis
- 8.1. Regional Dashboard
- 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
- 8.3. Northeast
- 8.3.1. Competitive scenario
- 8.3.2. Northeast small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.3.3. New Jersey
- 8.3.3.1. Competitive scenario
- 8.3.3.2. New Jersey small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.3.4. New York
- 8.3.4.1. Competitive scenario
- 8.3.4.2. New York small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.3.5. Massachusetts
- 8.3.5.1. Competitive scenario
- 8.3.5.2. Massachusetts small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.4. Midwest
- 8.4.1. Competitive scenario
- 8.4.2. Midwest small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.4.3. Illinois
- 8.4.3.1. Competitive scenario
- 8.4.3.2. Illinois small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.4.4. Missouri
- 8.4.4.1. Competitive scenario
- 8.4.4.2. Missouri small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.4.5. North Carolina
- 8.4.5.1. Competitive scenario
- 8.4.5.2. North Carolina small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5. West Group
- 8.5.1. Competitive scenario
- 8.5.2. West Group small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5.3. California
- 8.5.3.1. Competitive scenario
- 8.5.3.2. California small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.5.4. Washington
- 8.5.4.1. Competitive scenario
- 8.5.4.2. Washington small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6. South
- 8.6.1. Competitive scenario
- 8.6.2. South small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.3. Texas
- 8.6.3.1. Competitive scenario
- 8.6.3.2. Texas small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.4. Florida
- 8.6.4.1. Competitive scenario
- 8.6.4.2. Florida small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.6.5. Georgia
- 8.6.5.1. Competitive scenario
- 8.6.5.2. Georgia small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company Categorization
- 9.2. Company Market Position Analysis, 2024
- 9.3. Company Profiles
- 9.3.1. Lonza Group Ltd.
- 9.3.1.1. Company overview
- 9.3.1.2. Financial performance
- 9.3.1.3. Service benchmarking
- 9.3.1.4. Strategic initiatives
- 9.3.2. Novo Holdings (Catalent, Inc.)
- 9.3.2.1. Company overview
- 9.3.2.2. Financial performance
- 9.3.2.3. Service benchmarking
- 9.3.2.4. Strategic initiatives
- 9.3.3. Thermo Fisher Scientific, Inc.
- 9.3.3.1. Company overview
- 9.3.3.2. Financial performance
- 9.3.3.3. Service benchmarking
- 9.3.3.4. Strategic initiatives
- 9.3.4. Siegfried Holding AG
- 9.3.4.1. Company overview
- 9.3.4.2. Financial performance
- 9.3.4.3. Service benchmarking
- 9.3.4.4. Strategic initiatives
- 9.3.5. Recipharm AB
- 9.3.5.1. Company overview
- 9.3.5.2. Financial performance
- 9.3.5.3. Service benchmarking
- 9.3.5.4. Strategic initiatives
- 9.3.6. CordenPharma International
- 9.3.6.1. Company overview
- 9.3.6.2. Financial performance
- 9.3.6.3. Service benchmarking
- 9.3.6.4. Strategic initiatives
- 9.3.7. Samsung Biologics
- 9.3.7.1. Company overview
- 9.3.7.2. Financial performance
- 9.3.7.3. Service benchmarking
- 9.3.7.4. Strategic initiatives
- 9.3.8. Labcorp
- 9.3.8.1. Company overview
- 9.3.8.2. Financial performance
- 9.3.8.3. Service benchmarking
- 9.3.8.4. Strategic initiatives
- 9.3.9. Ajinomoto Bio-Pharma Services
- 9.3.9.1. Company overview
- 9.3.9.2. Financial performance
- 9.3.9.3. Service benchmarking
- 9.3.9.4. Strategic initiatives
- 9.3.10. Piramal Pharma Solutions
- 9.3.10.1. Company overview
- 9.3.10.2. Financial performance
- 9.3.10.3. Service benchmarking
- 9.3.10.4. Strategic initiatives
- 9.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
- 9.3.11.1. Company overview
- 9.3.11.2. Financial performance
- 9.3.11.3. Service benchmarking
- 9.3.11.4. Strategic initiatives
- 9.3.1. Lonza Group Ltd.
Product Code: GVR-4-68040-297-9
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviations
- Table 3 U.S. small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 4 U.S. small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 5 U.S. small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 6 U.S. small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 7 U.S. small molecule innovator API CDMO market estimates and forecasts, by region, 2018 - 2030 (USD Million)
- Table 8 Northeast small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
- Table 9 Northeast small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 10 Northeast small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 11 Northeast small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 12 Northeast small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 13 New Jersey small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 14 New Jersey small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 15 New Jersey small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 16 New Jersey small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 17 New York small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 18 New York small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 19 New York small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 20 New York small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 21 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 22 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 23 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 24 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 25 Midwest small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
- Table 26 Midwest small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 27 Midwest small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 28 Midwest small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 29 Midwest small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 30 Missouri small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 31 Missouri small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 32 Missouri small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 33 Missouri small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 34 North Carolina small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 35 North Carolina small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 36 North Carolina small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 37 North Carolina small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 38 West Group small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
- Table 39 West Group small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 40 West Group small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 41 West Group small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 42 West Group small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 43 California small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 44 California small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 45 California small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 46 California small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 47 Washington small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 48 Washington small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 49 Washington small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 50 Washington small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 51 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
- Table 52 South small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 53 South small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 54 South small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 55 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
- Table 56 Texas small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 57 Texas small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 58 Texas small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 59 Texas small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 60 Florida small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 61 Florida small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 62 Florida small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 63 Florida small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
- Table 64 Georgia small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
- Table 65 Georgia small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
- Table 66 Georgia small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
- Table 67 Georgia small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Information procurement
- Fig. 2 Primary research pattern
- Fig. 3 Market research approaches
- Fig. 4 Value chain-based sizing & forecasting
- Fig. 5 Market formulation & validation
- Fig. 6 small molecule innovator API CDMO market, Segmentation
- Fig. 7 Market driver analysis
- Fig. 8 Market restraint relevance analysis
- Fig. 9 Porter's five forces analysis
- Fig. 10 PESTEL by SWOT analysis
- Fig. 11 Regional marketplace: Key takeaways
- Fig. 12 U.S. preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 13 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 14 U.S. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 15 U.S. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 16 U.S. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 17 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 18 U.S. process development market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 19 U.S. preclinical development market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 20 U.S. clinical development market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 21 U.S. scale-up optimization market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 22 U.S. contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 23 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 24 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 25 U.S. analytical testing and quality control market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 26 U.S. packaging and supply chain solutions market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 27 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 28 U.S. pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 29 U.S. small pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 30 U.S. medium pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 31 U.S. large pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 32 U.S. biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 33 U.S. small biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 34 U.S. medium biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 35 U.S. large biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 36 U.S. cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 37 U.S. oncology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 38 U.S. respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 39 U.S. neurology market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 40 U.S. metabolic disorders market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 41 U.S. infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 42 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 43 Regional Outlook, 2024 & 2030
- Fig. 44 Northeast small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 45 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 46 New York small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 47 Massachusetts small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 48 Midwest small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 49 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 50 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 51 North Carolina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 52 West Group small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 53 California small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 54 Washington small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 55 South small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 56 Texas small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 57 Florida small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 58 Georgia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.